Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listFrovatriptan Succinate

Frovatriptan Succinate

Synonym(s):Frovatriptan succinate;Frovatriptan succinate monohydrate;R-(+) 3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole monosuccinate monohydrate

Frovatriptan Succinate Structural

What is Frovatriptan Succinate?

Description

Frovatriptan succinate was launched as an oral treatment for acute migraine attacks with or without aura in adults. It is the eighth member of the “triptan” class. Frovatriptan is a conformationally-restricted analog of the 5-HT1-receptor agonist 5-carboxytryptamine which can be prepared in six steps. The key intermediate (R)-6-cyano-3-N-methylamino- 1,2,3,4-tetrahydrocarbazole is obtained by Fischer reaction of 4-cyanophenylhydrazine with the appropriate ketone followed by resolution using L-pyroglutamic acid. This drug acts as a dual 5-HT1D/1B receptor partial agonist and has high and selective affinity for 5HT1B and 5-HT1D receptors in cranial vessels. It has no significant activity at 5-HT2, 5-HT3, 5-HT4, α-adrenergic, histaminergic or GABAA receptors. Frovatriptan is also a moderately potent full agonist at 5-HT7 receptors, which have a dilatory action and are expressed in the human coronary artery. In vitro studies appear to indicate frovatriptan’s functional selectivity for cerebral circulation as shown by the concentrations needed to induce threshold contractile activity and maximum response in basilar arteries as compared with coronary arteries. Frovatriptan is mainly metabolized by CYPlA2 and most of its metabolites are excreted renally. Co-administration of frovatriptan with the monoamine oxidase-A inhibitor moclobemide or with the potent CYPlA2 inhibitor fluvoxamine did not affect its pharmacokinetics parameters. Although frovatriptan has a poor bioavailability (24- 30%), it has a very long half-life compared to other triptans (25 h) and has an onset of action and efficacy similar to those of naratriptan. The most striking features of this drug are the low headache recurrence rate, which is one of the lowest among the triptans and which may be attributed to its long half-life, and excellent tolerance profile. No significant effect on the cardiovascular system was seen after administration of a single oral dose of 14 fold the therapeutic dose of frovatriptan.

Originator

GlaxoSmithKlineNernaIis (UK)

Manufacturing Process

4-Carboxamidophenylhydrazine hydrochloride (2.87 g) and 4- phthalimidocyclohexanone (3.00 g) were mixed in acetic acid and the mixture was heated under reflux for 2 h. After cooling, the mixture was neutralized using aq. potassium carbonate solution, and the yellow solid thus obtained was filtered, washed with water, and dried. Purification by column chromatography (SiO2; CHCl3/CH3OH) gave 6-carboxamido-3-phthalimido- 1,2,3,4-tetrahydrocarbazole (2.8 g).
The 6-carboxamido-3-phthalimido-1,2,3,4-tetrahydrocarbazole (1.0 g) was suspended in ethanol (10 ml) and hydrazine hydrate (5 ml) was added. A clear solution was obtained, and the mixture was left to stir overnight, to yield a precipitate. The whole mixture was evaporated to dryness, washed with aq. K2CO3 solution, and water, to leave the (+/-)-3-amino-6-carboxamido-1,2,3,4- tetrahydrocarbazole (0.44 g), melting point 146°-148°C.
Separation of diastereoisomers of a chiral derivative of a 3-amino-6- carboxamido-1,2,3,4-tetrahydrocarbazole e.g. by crystallisation, or by chromatography.
Benzaldehyde (10.6 g) was added to a suspension of (+)-3-amino-6- carboxamido-1,2,3,4-tetrahydrocarbazole (12.35 g) in methanol (100 ml). The mixture was stirred for 1 h, sodium cyanoborohydride (9.3 g) added over 1 h and the clear solution stirred for 24 h. The solution was cooled (ice bath) and formaldehyde (37% aqueous methanolic, 9:1 solution, 5.5 ml) added. After 30 min stirring at room temperature water (100 ml) was added, stirring continued for 30 min followed by extraction with dichloromethane (3 times 150 ml). The combined organic extracts were washed with water (2 times 200 ml), dried (Na2SO4), filtered and solvent removed at reduced pressure. The residue was column chromatographed (silica gel, dichloromethane-10% ethanol/dichloromethane) to give 3-N-benzyl-6-carboxamido-3-Nmethylamino-1,2,3,4-tetrahydrocarbazole (9.4 g) as a foam. The succinate salt (1:1) was recrystallised from methanol, melting point 175°-182°C.
To a solution of 3-N-benzyl-6-carboxamido-3-N-methylamino-1,2,3,4- tetrahydrocarbazole (1.0 g) in ethanol (100 ml) containing succinic acid (0.39 g), Pearlmans catalyst (1.0 g) was added and the mixture shaken under an atmosphere of hydrogen at 45 psi and 50°C for 2 h. The mixture was filtered (celite pad) and the pad washed thoroughly with ethanol. The combined flitrate and washings were evaporated to dryness, coevaporated with ethanol (3 times 100 ml) and recrystallised from methanol to give the (+)-6- carboxamido-3-N-methylamino-1,2,3,4-tetrahydrocarbazole succinate (1:1) salt, melting point 148°-155°C.

brand name

Frova

Therapeutic Function

Migraine therapy

Synthesis

The synthesis of frovatriptan (11) appeared in a patent in multi-kilo scale. Cyclohexanedione monoketal (121) was converted to amine 122 by reductive amination. The Fischer indolization of amine 122 with hydrazine 123 furnished indole nitrile 124 in 72% yield. The desired R isomer of the indole nitrile was obtained via a chiral salt formation/recrystallization process using chiral lactam 125 and isolated as a L-pyroglutamic acid salt 126. Hydrolysis of the nitrile functional group in 126 provided carboxamido indole 127, which was converted to succinate 11 in situ.

Synthesis_158930-09-7

Properties of Frovatriptan Succinate

storage temp.  Store at -20°C
solubility  DMSO: 72 mg/mL (199.23 mM);Ethanol: Insoluble
Water Solubility  Water: 72 mg/mL (199.23 mM)

Safety information for Frovatriptan Succinate

Computed Descriptors for Frovatriptan Succinate

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.